Literature DB >> 2143893

Treatment of hypercalcaemia of malignancy.

D A Heath.   

Abstract

Hypercalcaemia is a common complication of malignancy. When severe, if treatment is thought to be justified, it should be treated with 2-3 litres of intravenous fluids per day combined with administration of an intravenous bisphosphonate drug. Mild to moderate hypercalcaemia is more difficult to manage satisfactorily. Oral steroids can be tried but are often ineffective, oral phosphate is effective but causes side-effects. It is likely that active oral bisphosphonate drugs will soon be available and these are likely to become the treatment of choice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143893     DOI: 10.1016/s0950-351x(05)80320-9

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  1 in total

1.  Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism.

Authors:  A C Hutchesson; N J Bundred; W A Ratcliffe
Journal:  Postgrad Med J       Date:  1995-01       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.